VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

August 31, 2026

Conditions
Colitis, Ulcerative
Interventions
DRUG

VTX002

Dose A tablet administered orally once daily

DRUG

VTX002

Dose B Tablet administered orally once daily

DRUG

Placebo

Placebo Tablet for VTX002 administered orally once daily

Trial Locations (77)

29572

Local Site # 840045, Myrtle Beach

30342

Local Site # 840018, Atlanta

33165

Local Site # 840006, Miami

34744

Local Site # 840049, Kissimmee

45415

Local Site # 840043, Dayton

47150

Local Site # 840046, New Albany

48197

Local Site # 840044, Ypsilanti

71105

Local Site # 840042, Shreveport

73101

Local Site # 840010, Oklahoma City

75044

Local Site # 840013, Garland

75701

Local Site # 840028, Tyler

76092

Local Site # 840016, Southlake

78503

Local Site # 840033, McAllen

78666

Local Site # 840007, San Marcos

79424

Local Site # 8400039, Lubbock

92123

Local Site # 840040, San Diego

92845

Local Site # 840030, Garden Grove

93003

Local Site # 840001, Ventura

93534

Local Site # 840026, Lancaster

Unknown

Local Site # 100002, Rousse

Local Site # 100005, Rousse

Local Site # 203002, Hradec Králové

Local Site # 203001, Slaný

Local Site # 203004, Ústí nad Labem

Local Site # 250004, Caen

Local Site # 250001, Nantes

Local Site # 250003, Vandœuvre-lès-Nancy

Local Site # 268001, Tbilisi

Local Site # 268002, Tbilisi

Local Site # 268003, Tbilisi

Local Site # 268004, Tbilisi

Local Site # 268005, Tbilisi

Local Site # 268006, Tbilisi

Local Site # 276005, Berlin

Local Site # 276008, Brandenburg

Local Site # 276007, Duisburg

Local Site # 276009, Halle

Local Site # 276003, Nordhausen

Local Site # 348004, Békéscsaba

Local Site # 348001, Budapest

Local Site # 348003, Budapest

Local Site # 348002, Székesfehérvár

Local Site # 356001, Ahmedabad

Local Site # 356003, Jaipur

Local Site # 356005, Sūrat

Local Site # 380009, Milan

Local Site # 380001, Negrar

Local Site # 380004, Pavia

Local Site # 380008, Rome

Local Site # 380002, San Giovanni Rotondo

Local Site # 440002, Panevezys

Local Site # 440001, Vilnius

Local Site # 616010, Bydgoszcz

Local Site # 616012, Jelenia Góra

Local Site # 616001, Lodz

Local Site # 616017, Lodz

Local Site # 616015, Lublin

Local Site # 616004, Oświęcim

Local Site # 616011, Piotrkow Trybunalski

Local Site # 616008, Poznan

Local Site # 616014, Rzeszów

Local Site # 616007, Sosnowiec

Local Site # 616003, Warsaw

Local Site # 616006, Warsaw

Local Site # 616002, Wroclaw

Local Site # 616009, Wroclaw

Local Site # 616013, Wroclaw

Local Site # 688002, Belgrade

Local Site # 688003, Belgrade

Local Site # 688004, Belgrade

Local Site # 688001, Zrenjanin

Local Site # 703001, Košice

Local Site # 703003, Prešov

Local Site # 703002, Šahy

Local Site # 410003, Daegu

Local Site # 410002, Seoul

Local Site # 410004, Wŏnju

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oppilan Pharma Ltd

INDUSTRY

NCT05156125 - VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter